The Peptide Chronicle

Science, Policy & Truth

Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.

Tag: Glucagon

Retatrutide Online Safety in 2026: Why the Triple-Agonist Peptide Is Trending Today

Retatrutide is surging in search and social conversation. Alex Keane explains the triple-agonist science, clinical data, and online peptide safety risks behind today’s trend.

Retatrutide Peptide Safety GLP-1 GIP

June 24, 20268 min read

Read Article ›

Peptide Safety

Retatrutide Is Trending Again: What Triple-Agonist Data Means for Peptide Safety in 2026

Retatrutide is driving a new wave of peptide searches after Phase 3 weight-loss data. Alex Keane explains the triple-agonist science, safety signals, and why online peptide products deserve caution.

Retatrutide Peptide Safety GLP-1 GIP

June 23, 20268 min read

Read Article ›

Science, Policy & Truth

Recent Posts

Retatrutide Online Safety in 2026: Why the Triple-Agonist Peptide Is Trending Today

Retatrutide Is Trending Again: What Triple-Agonist Data Means for Peptide Safety in 2026